论文部分内容阅读
目的:检测非小细胞肺癌(non-small cell lung cancer,NSCLC)患者外周血抗Hu抗体水平与健康志愿者抗Hu抗体水平进行比较,并分析其与肿瘤转移部位和多种临床病理变量间的关系。方法:收集济南军区总医院肿瘤科2013年6月至2013年12月NSCLC患者外周血清标本75例,同时收集成年健康志愿者外周血清标本100例(除外肿瘤及神经系统疾病史)作为阴性对照,按照酶联免疫吸附试验原理,检测175例血清抗Hu抗体表达。纳入研究的变量主要包括:75例NSCLC患者的性别、年龄、组织类型、核分化级别、EGFR突变状态、肿瘤标志物(CEA、CY21-1和NSE)水平及远处转移部位(脑转移、骨转移及其他部位转移)。结果:肺癌患者外周血抗Hu抗体水平[(40.00±35.76)ng/ml]显著高于健康人群[(16.40±8.19)ng/ml,P=0.000]。75例患者中有62.67%(47/75)抗Hu抗体高水平表达,37.33%(28/75)呈低表达。外周血抗Hu抗体水平与患者脑转移(P=0.015)显著相关;81.81%(9/11)的脑转移患者检测到高水平的抗Hu抗体,但仅仅50.00%(32/64)的非脑转移患者检测到高水平的抗Hu抗体;抗Hu抗体水平与患者性别、年龄、组织类型、分期、EGFR突变、CEA水平、CY21-1、NSE、骨转移及其他部位转移无关(P>0.05)。多变量回归分析显示,外周血中抗Hu抗体水平是预测脑转移的独立变量(P=0.015)。结论:非小细胞肺癌患者外周血中抗Hu抗体呈高水平,与脑转移显著相关。抗Hu抗体在非小细胞肺癌脑转移中的作用机制尚需进一步明确。
Objective: To detect the level of anti-Hu antibody in peripheral blood of non-small cell lung cancer (NSCLC) patients and compare the level of anti-Hu antibody in healthy volunteers, and to analyze the relationship between anti-Hu antibody and tumor metastasis sites and various clinicopathological variables relationship. Methods: Seventy-five NSCLC peripheral blood samples were collected from June 2013 to December 2013 in the Department of Oncology, Jinan Military Region General Hospital, 100 peripheral blood serum samples of healthy volunteers were collected from the healthy volunteers (excluding the history of tumor and nervous system diseases) as negative control, According to the principle of enzyme-linked immunosorbent assay, 175 cases of serum anti-Hu antibody was detected. The variables included in the study included gender, age, histological type, level of nuclear differentiation, EGFR mutation status, levels of tumor markers (CEA, CY21-1 and NSE) and distant metastases (brain metastases, bone Transfer and other parts of the transfer). Results: The level of anti-Hu antibody in peripheral blood of patients with lung cancer [(40.00 ± 35.76) ng / ml] was significantly higher than that of healthy people [(16.40 ± 8.19) ng / ml, P = 0.000]. Among the 75 patients, 62.67% (47/75) showed high levels of anti-Hu antibody and 37.33% (28/75) showed low expression. The levels of anti-Hu antibody in peripheral blood were significantly correlated with brain metastases (P = 0.015). High levels of anti-Hu antibodies were detected in 81.81% (9/11) of brain metastases, but only 50.00% (32/64) The level of anti-Hu antibody was not correlated with gender, age, histological type, staging, EGFR mutation, CEA level, CY21-1, NSE, bone metastasis and other site metastases (P> 0.05) . Multivariate regression analysis showed that anti-Hu antibody levels in peripheral blood were independent predictors of brain metastases (P = 0.015). Conclusion: The anti-Hu antibody in peripheral blood of patients with non-small cell lung cancer is high, which is significantly correlated with brain metastasis. Anti-Hu antibody in non-small cell lung cancer brain metastasis mechanism needs further clarification.